Giles Campion
Overview
Explore the profile of Giles Campion including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
509
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rider D, Chivers S, Aretz J, Eisermann M, Loffler K, Hauptmann J, et al.
Toxicol Sci
. 2022 Jun;
189(2):237-249.
PMID: 35737426
SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing lipoprotein (a)-related cardiovascular risk. Here, we describe the findings from key preclinical safety...
2.
Rider D, Eisermann M, Loffler K, Aleku M, Swerdlow D, Dames S, et al.
Atherosclerosis
. 2022 Apr;
349:240-247.
PMID: 35400495
Background And Aims: The LPA gene encodes apolipoprotein (a), a key component of Lp(a), a potent risk factor for cardiovascular disease with no specific pharmacotherapy. Here we describe the pharmacological...
3.
McDonald C, Wong B, Flanigan K, Wilson R, de Kimpe S, Lourbakos A, et al.
Ann Clin Transl Neurol
. 2018 Aug;
5(8):913-926.
PMID: 30128316
Objective: This double-blind, randomized, placebo-controlled Phase 2 study (NCT01462292) assessed the 24-week efficacy, safety, tolerability, and pharmacokinetics of two different subcutaneous drisapersen doses, and the 24-week off-dose persistent effect, in...
4.
Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald C, et al.
Neuromuscul Disord
. 2017 Dec;
28(1):4-15.
PMID: 29203355
This 48-week, randomized, placebo-controlled phase 3 study (DMD114044; NCT01254019) evaluated efficacy and safety of subcutaneous drisapersen 6 mg/kg/week in 186 ambulant boys aged ≥5 years, with Duchenne muscular dystrophy (DMD)...
5.
Goemans N, Tulinius M, Kroksmark A, Wilson R, Van den Hauwe M, Campion G
Neuromuscul Disord
. 2017 Feb;
27(3):203-213.
PMID: 28169120
Duchenne muscular dystrophy is a rare genetic disorder with life-limiting pathology. Drisapersen induces exon 51 skipping, thereby producing a shorter but functional dystrophin protein. The longest available data are from...
6.
Goemans N, Tulinius M, Van den Hauwe M, Kroksmark A, Buyse G, Wilson R, et al.
PLoS One
. 2016 Sep;
11(9):e0161955.
PMID: 27588424
Background: Drisapersen induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations. Methods: This 188-week open-label...
7.
Straub V, Balabanov P, Bushby K, Ensini M, Goemans N, De Luca A, et al.
Lancet Neurol
. 2016 Jun;
15(8):882-890.
PMID: 27302365
Duchenne muscular dystrophy is a rare, progressive, muscle-wasting disease leading to severe disability and premature death. Treatment is currently symptomatic, but several experimental therapies are in development. Implemented care standards,...
8.
Anthony K, Arechavala-Gomeza V, Taylor L, Vulin A, Kaminoh Y, Torelli S, et al.
Neurology
. 2014 Oct;
83(22):2062-9.
PMID: 25355828
Objective: We formed a multi-institution collaboration in order to compare dystrophin quantification methods, reach a consensus on the most reliable method, and report its biological significance in the context of...
9.
Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al.
Lancet Neurol
. 2014 Sep;
13(10):987-96.
PMID: 25209738
Background: Duchenne muscular dystrophy is caused by dystrophin deficiency and muscle deterioration and preferentially affects boys. Antisense-oligonucleotide-induced exon skipping allows synthesis of partially functional dystrophin. We investigated the efficacy and...
10.
Flanigan K, Voit T, Rosales X, Servais L, Kraus J, Wardell C, et al.
Neuromuscul Disord
. 2013 Dec;
24(1):16-24.
PMID: 24321374
Duchenne muscular dystrophy (DMD) is a progressive, lethal neuromuscular disorder caused by the absence of dystrophin protein due to mutations of the dystrophin gene. Drisapersen is a 2'-O-methyl-phosphorothioate oligonucleotide designed...